会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明公开
    • 의존성 금단의 치료
    • 治疗依法撤销
    • KR1020060037400A
    • 2006-05-03
    • KR1020067001688
    • 2004-07-26
    • 유로-셀띠끄 소시에떼 아노님
    • 레이덴버그브루스이스파이커다니엘에이
    • A61M37/00A61B19/00
    • A61K9/7023A61K31/485A61L15/00B09B2220/14
    • Dosage regimens of buprenorphine to treat withdrawal or abstinence syndrome in a drug dependent or opioid tolerant patient who is pregnant are described. The method includes treating withdrawal or abstinence syndrome of the patient by transdermal administration of an amount of buprenorphine effective to reduce withdrawal symptoms. For example, a first buprenorphine-containing transdermal dosage form can be administered for a first dosing period that is no more than about 5 days; a second buprenorphine-containing transdermal dosage form for a second dosing period that is no more than about 5 days, the second dosage form comprising the same or a greater dosage of buprenorphine than the first dosage form; and a third buprenorphine-containing transdermal dosage form for a third dosing period that is at least 2 days, the third dosage form comprising the same or a greater dosage of buprenorphine than the second dosage form.
    • 描述了丁丙诺啡在怀孕的药物依赖性或阿片受体患者中治疗戒断或禁欲综合征的剂量方案。 该方法包括通过透皮给药一定量的丁丙诺啡来治疗患者的戒断或禁欲综合征,所述丁丙诺啡有效地减少戒断症状。 例如,可以在不超过约5天的第一给药期间施用第一种含丁丙诺啡的透皮剂型, 第二给药期间不超过约5天的第二种含丁丙诺啡的透皮剂型,所述第二剂型包含与第一剂型相同或更高剂量的丁丙诺啡; 和含有至少2天的第三给药期的第三种含丁丙诺啡的透皮剂型,所述第三剂型包含与第二剂型相同或更高剂量的丁丙诺啡。